Sunday, October 02, 2022 7:25:48 AM
The PRs and statements at conferences in the last 10 odd years give us enough evidence that they have been BSing us, no?
From official statements in mid 2010s saying data lock coming soon to presentation by LP to scientific community in summer of 2020 at a virtual meeting that we will be unblinding in the coming weeks to LG’s appearance on big booze show in summer 2020 saying UK approval imminent….what additional proof do you need?
They have not been able to tackle the shorts for over 10 years now. They know what was coming and yet botched May 10. Given their repeated failures, no guarantee it won’t happen again. You could argue this is done to benefit a narrow set of investors to pump and dump, suck more retail.
Why are they hiding behind the quiet period for 2 years post data lock when they ought to be going out there convincing the street as to the real value of our platform, particularly with the stellar ph 3 data. Something smells fishy? Give me example of one successful biotech company that has taken this strategy? Importantly, why would you dilute the company at such low share price when you are in possession of such great data for months now and approvals that are imminent? The investors ought to be dancing on our tunes to invest in us!
From official statements in mid 2010s saying data lock coming soon to presentation by LP to scientific community in summer of 2020 at a virtual meeting that we will be unblinding in the coming weeks to LG’s appearance on big booze show in summer 2020 saying UK approval imminent….what additional proof do you need?
They have not been able to tackle the shorts for over 10 years now. They know what was coming and yet botched May 10. Given their repeated failures, no guarantee it won’t happen again. You could argue this is done to benefit a narrow set of investors to pump and dump, suck more retail.
Why are they hiding behind the quiet period for 2 years post data lock when they ought to be going out there convincing the street as to the real value of our platform, particularly with the stellar ph 3 data. Something smells fishy? Give me example of one successful biotech company that has taken this strategy? Importantly, why would you dilute the company at such low share price when you are in possession of such great data for months now and approvals that are imminent? The investors ought to be dancing on our tunes to invest in us!
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
